2006
Tu-P10:495 Serum level of soluble receptor for advanced glycation end products is associated with circulating advanced glycation end products in type 2 diabetes
Tan K, Chow W, Shiu S, Bucala R, Betteridge D. Tu-P10:495 Serum level of soluble receptor for advanced glycation end products is associated with circulating advanced glycation end products in type 2 diabetes. Atherosclerosis Plus 2006, 7: 294. DOI: 10.1016/s1567-5688(06)81196-7.Peer-Reviewed Original ResearchAdvanced glycation end productsGlycation end productsType 2 diabetesSerum levelsSoluble receptorEnd productsDiabetes
2002
New horizons in AGE research
Bucala R. New horizons in AGE research. International Congress Series 2002, 1245: 113-117. DOI: 10.1016/s0531-5131(02)00886-5.Peer-Reviewed Original ResearchAdvanced glycation end productsRecent human clinical studiesGlycation end productsHuman clinical studies
2001
Immunological Detection of a Novel Advanced Glycation End-Product
Takeuchi M, Yanase Y, Matsuura N, Yamagishi S, Kameda Y, Bucala R, Makita Z. Immunological Detection of a Novel Advanced Glycation End-Product. Molecular Medicine 2001, 7: 783-791. PMID: 11788793, PMCID: PMC1950006, DOI: 10.1007/bf03401969.Peer-Reviewed Original Research
2000
Neurotoxicity of Advanced Glycation End-Products for Cultured Cortical Neurons
Takeuchi M, Bucala R, Suzuki T, Ohkubo T, Yamazaki M, Koike T, Kameda Y, Makita Z. Neurotoxicity of Advanced Glycation End-Products for Cultured Cortical Neurons. Journal Of Neuropathology & Experimental Neurology 2000, 59: 1094-1105. PMID: 11138929, DOI: 10.1093/jnen/59.12.1094.Peer-Reviewed Original ResearchConceptsCortical neuronsAge 2Alzheimer's diseaseEnd-stage renal diseaseNeuronal cellsAdvanced glycation end productsDM HD patientsGreater cytopathic effectsSpecific antibodiesAnti-AGE antibodyCultured cortical neuronsDose-dependent increaseGlycation end productsBlood of individualsCultured neuronal cellsDiabetes mellitusDiabetic patientsRenal diseaseNeurodegenerative processesNormal controlsAdvanced glycationCytopathic effectEpitope 1Cytotoxic effectsMTT assayImmunological Evidence that Non-carboxymethyllysine Advanced Glycation End-products Are Produced from Short Chain Sugars and Dicarbonyl Compounds in vivo
Takeuchi M, Makita Z, Bucala R, Suzuki T, Koike T, Kameda Y. Immunological Evidence that Non-carboxymethyllysine Advanced Glycation End-products Are Produced from Short Chain Sugars and Dicarbonyl Compounds in vivo. Molecular Medicine 2000, 6: 114-125. PMID: 10859028, PMCID: PMC1949938, DOI: 10.1007/bf03401779.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodiesCattleChromatography, AffinityCross ReactionsDiabetes Mellitus, Type 2Enzyme-Linked Immunosorbent AssayGlycation End Products, AdvancedGlyceraldehydeGlyoxalHumansImmunoblottingKidney Failure, ChronicLysineMaillard ReactionOxidation-ReductionPyruvaldehydeRabbitsRenal DialysisConceptsAGE antibodyCML-AGEDiabetic patientsAGE-bovine serum albuminShort Chain SugarsAdvanced glycation end productsAnti-AGE antibodyGlycation end productsAutoxidation of sugarsImmunization of rabbitsCML-BSADiabetic serumSerum albuminAdvanced glycationAGE contentSugar autoxidationRabbit serum albuminAGE modificationAntibodiesImmunological evidenceApparent molecular weightPatientsAge 3AgeImmunoblot analysis
1999
Structure of a Synthetic Glucose Derived Advanced Glycation End Product That Is Immunologically Cross-Reactive with Its Naturally Occurring Counterparts †
Al-Abed Y, Bucala R. Structure of a Synthetic Glucose Derived Advanced Glycation End Product That Is Immunologically Cross-Reactive with Its Naturally Occurring Counterparts †. Bioconjugate Chemistry 1999, 11: 39-45. PMID: 10639083, DOI: 10.1021/bc990061q.Peer-Reviewed Original ResearchConceptsAdvanced glycation end productsAnti-AGE antibodyGlycation end productsLow-density lipoproteinAGE-modified formCertain diabetic complicationsClasses of antibodiesBeta-amyloid peptideDiabetic complicationsPathological sequelaePrognostic informationAGE formationAGE adductsImmunoreactive fractionEnd productsInhibition of formationVivo ageAgeAntibodiesLines of evidenceVivoCross-linking adductsGlucoseTissueComplications
1998
Epitopes close to the apolipoprotein B low density lipoprotein receptor-binding site are modified by advanced glycation end products
Wang X, Bucala R, Milne R. Epitopes close to the apolipoprotein B low density lipoprotein receptor-binding site are modified by advanced glycation end products. Proceedings Of The National Academy Of Sciences Of The United States Of America 1998, 95: 7643-7647. PMID: 9636203, PMCID: PMC22709, DOI: 10.1073/pnas.95.13.7643.Peer-Reviewed Original ResearchConceptsAdvanced glycation end productsLow-density lipoproteinGlycation end productsLDL receptorAGE modificationAbnormal lipoprotein profilesGlycation of LDLInability of LDLPrevious immunochemical studiesRenal failureLipoprotein profileTime-dependent decreaseCardiovascular diseaseApolipoprotein BAdvanced glycationDensity lipoproteinReceptor-binding siteEnd productsImmunochemical studiesEpitopesGlycationCellular uptakeMultiple sitesPatientsDiabetes
1997
Tobacco smoke is a source of toxic reactive glycation products
Cerami C, Founds H, Nicholl I, Mitsuhashi T, Giordano D, Vanpatten S, Lee A, Al-Abed Y, Vlassara H, Bucala R, Cerami A. Tobacco smoke is a source of toxic reactive glycation products. Proceedings Of The National Academy Of Sciences Of The United States Of America 1997, 94: 13915-13920. PMID: 9391127, PMCID: PMC28407, DOI: 10.1073/pnas.94.25.13915.Peer-Reviewed Original ResearchConceptsAdvanced glycation end productsTobacco smokeGlycation productsAGE formationSerum AGE levelsIncidence of atherosclerosisPlasma of patientsGlycation end productsRenal insufficiencyCerebrovascular diseaseCigarette smokersHuman smokersHigh prevalenceHigh riskSmokersNonsmokersGlycotoxinsPatientsSpecific fluorescenceSerum proteinsDiseaseCuring of tobaccoAqueous extractSmokeTobaccoEfficient Scavenging of Fatty Acid Oxidation Products by Aminoguanidine
Al-Abed Y, Bucala R. Efficient Scavenging of Fatty Acid Oxidation Products by Aminoguanidine. Chemical Research In Toxicology 1997, 10: 875-879. PMID: 9282836, DOI: 10.1021/tx970035l.Peer-Reviewed Original ResearchConceptsLow-density lipoprotein levelsAdvanced glycation end productsGlycation end productsMechanism of actionVascular wall componentsLipoprotein levelsLipoprotein metabolismOxidative stressPharmacological inhibitorsFatty acid oxidation productsHuman subjectsToxic effectsAminoguanidineOxidative damageNormal pathwayReactive aldehydesRecent studiesPotential interactionsDamaging effectsVivoTissue constituentsEnd productsAtherogenesisLipid oxidationMalondialdehyde
1996
Glycation and microglial reaction in lesions of Alzheimer's disease
Dickson D, Sinicropi S, Yen S, Ko L, Mattiace L, Bucala R, Vlassara H. Glycation and microglial reaction in lesions of Alzheimer's disease. Neurobiology Of Aging 1996, 17: 733-743. PMID: 8892346, DOI: 10.1016/0197-4580(96)00116-9.Peer-Reviewed Original ResearchConceptsAdvanced glycation end productsAGE immunoreactivityNeurofibrillary tanglesExtracellular neurofibrillary tanglesAmyloid depositsMicroglial reactionActivation of microgliaIntracellular neurofibrillary tanglesAlzheimer's disease brainPattern of immunoreactivityGlycation end productsTriple immunostainingDisease brainSenile plaquesDiffuse amyloidAlzheimer's diseaseImmunoreactivityCryostat sectionsDouble labelingAntibodiesMicrogliaLesionsPolyclonal antibodiesDiseaseGlycationEffects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment
Soulis T, Cooper M, Vranes D, Bucala R, Jerums G. Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. Kidney International 1996, 50: 627-634. PMID: 8840295, DOI: 10.1038/ki.1996.358.Peer-Reviewed Original ResearchConceptsRenal advanced glycation end productsAdvanced glycation end productsExperimental diabetic nephropathyDiabetic nephropathyEffect of aminoguanidineDiabetic ratsAminoguanidine treatmentMesangial expansionStudy periodAccumulation of AGEsUrinary albumin excretionTiming of therapyDevelopment of albuminuriaWeeks of treatmentDuration of treatmentGlycation end productsTiming of treatmentPresence of aminoguanidineAminoguanidine administrationAminoguanidine therapyAlbumin excretionRenoprotective effectsTissue fluorescenceExperimental diabetesLate administration